KOSDAQElectronic Components041830

InBody

₩40,050▲ 1.91%2026-11-18 close
Market Cap
₩539.9B
Turnover
₩1B
Volume
20K
Shares out.
13.5M
PER
12.5×
PBR
1.5×
EPS
₩3,101
Dividend Yield
1.55%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩600 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas Sales Lift Operating Profit; Net Income Still Lags

InBody's third-quarter 2026 operating profit rose 96.5% year on year on North American growth, while net income attributable to owners fell 52.5% over the same quarter, so operating and bottom-line trends are diverging.

  1. 1

    Third-quarter 2026 sales reached KRW 71.3 billion, up 19.2% year on year, and operating profit reached KRW 19.3 billion, up 96.5%.

  2. 2

    Net income attributable to owners was KRW 4.58 billion, down 52.5% year on year and lower for two straight quarters; press analysis pointed to FX volatility and one-off costs.

  3. 3

    North American sales rose 34% to KRW 31.1 billion in the third quarter, and the US and Europe accounted for 66.8% of the first-half 2026 sales increase.

  4. 4

    Body composition analyzers made up 70.8% of first-half 2026 sales, while the LB software line accounted for only 3.4%.

  5. 5

    Mirae Asset Securities presented a target price of KRW 100,000 in a report covered in early November 2026, and Sangsangin Securities raised its target to KRW 85,000 in a report dated October 8, 2026.

02

Business structure

InBody, founded in 1996, makes body composition analysis equipment that measures water, fat, protein and minerals in the human body and sells it to hospitals, fitness centers and public institutions. In the first half of 2026, body composition analyzers generated about KRW 100.3 billion, or 70.8% of sales.

The LB integrated software, which manages accumulated measurement data, contributed about KRW 4.9 billion, or 3.4%, and consumables and other items made up 8.1%.

In the first quarter of 2026, professional-use analyzers and the BWA body water analyzer accounted for 71.0% of sales, consumer products such as home analyzers for 12.7%, and software for 3.6%. Exports were 87.3% of first-half 2026 sales.

By customer location, first-half US sales were about KRW 51 billion, up 37.3% year on year, while Europe (about KRW 19.8 billion) and Mexico (about KRW 8.3 billion) grew 44.9% and 60.3%. Direct sales generated 77.7% of first-half revenue rather than sales through distributors.

At the US subsidiary, hospitals and medical institutions made up 43.6% of sales, nearly double the 23.3% from fitness centers. Domestic sales fell 15% to KRW 8.6 billion in the third quarter, while home InBody products rose 14% to KRW 9.9 billion and medical devices fell 5% to KRW 2.9 billion.

A 2021 press report put InBody's share of the global body composition analyzer market at 50%, which would make it the industry leader. The company says its hardware installations have built up more than 250 million body composition records.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩59.8B₩9.8B16.4%
2025Q4₩62.4B₩9.5B15.3%
2026Q1₩68.4B₩13B19.0%
2026Q2₩73.3B₩17.7B24.2%
2026Q3₩71.3B₩19.3B27.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩160B₩40.7B₩33.8B25.4%15.7%12.3%
2023₩170.4B₩38.3B₩36.7B22.5%14.8%9.9%
2024₩204.5B₩36.7B₩33.1B18.0%12.1%11.7%
2025₩233.9B₩36.8B₩30.6B15.7%9.6%12.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On the basis of the audited annual filings, sales rose from KRW 160 billion in 2022 to KRW 170.4 billion in 2023, KRW 204.5 billion in 2024 and KRW 233.9 billion in 2025. Sales have increased for three consecutive years from 2023 through 2025, and 2025 sales were up 14.4% year on year.

Operating profit over the same period went from KRW 40.7 billion in 2022 to KRW 38.3 billion in 2023, down 5.8%, and KRW 36.7 billion in 2024, down 4.2%, before reaching KRW 36.8 billion in 2025, with no change from the prior year.

The operating margin narrowed from 25.4% in 2022 to 15.7% in 2025, so sales growth did not carry through to profit. The company has said that a few years of investment in overseas expansion and hiring raised its selling and administrative costs.

Net income attributable to owners peaked at KRW 36.7 billion in 2023, then fell to KRW 33.1 billion in 2024 (down 9.7%) and KRW 30.6 billion in 2025 (down 7.6%), a two-year decline. Net income including non-controlling interests was KRW 30 billion in 2025.

Operating cash flow recovered to KRW 35.8 billion in 2025 from KRW 28.6 billion in 2024. Quarterly results moved in a different direction.

Operating profit bottomed at KRW 9.52 billion in the fourth quarter of 2025, down 3.2% from the prior quarter, and then rose to KRW 13 billion, KRW 17.7 billion and KRW 19.3 billion over the next three quarters.

Sales peaked at KRW 73.3 billion in the second quarter of 2026 and slipped 2.7% to KRW 71.3 billion in the third quarter. Press reports put the third-quarter operating margin at 27.1%, up from 24.2% in the prior quarter.

Net income attributable to owners peaked at KRW 16.3 billion in the first quarter of 2026, then fell to KRW 14.2 billion and KRW 4.58 billion over the next two quarters. The last four quarters together total KRW 41.5 billion.

Daol Investment & Securities estimated that third-quarter operating profit would be KRW 13.1 billion excluding one-off items (report covered on November 6, 2026). In the preliminary disclosure of November 5, net income attributable to owners was KRW 4.75 billion (preliminary, before external audit).

05

Industry analysis

The demand backdrop for body composition analysis is the spread of GLP-1 obesity drugs. A company official said that more people now want to lose fat while limiting muscle loss during weight reduction.

The company has said that penetration of the body composition analysis market remains low, leaving room for further growth. Demand is moving in different directions at home and abroad: overseas sales kept growing at double-digit rates, while domestic sales fell 15% in the third quarter. Currency is also a variable.

Sangsangin Securities estimated that a weaker won trimmed analyzer export growth from 37.9% in the second quarter to about 27% in the third quarter. On competition, a 2021 press report put InBody's global share of body composition analyzers at 50%, but that figure is from 2021 and current shares may differ.

Unlike the professional-use analyzers that drove growth, medical devices fell 5% to KRW 2.9 billion in the third quarter. Overall, body composition analysis equipment is expanding with obesity-management demand, while overseas dependence and channel structure remain sources of earnings volatility.

06

Outlook

Securities estimates put InBody's 2026 consolidated sales at KRW 289.8 billion, up 23.9% year on year, and operating profit at KRW 56.9 billion, up 54.9% (Sangsangin Securities, report dated October 8, 2026). The same report projected 2027 sales of KRW 333.7 billion and operating profit of KRW 66.1 billion.

Sangsangin also expected sales growth to widen again in the fourth quarter, the seasonally stronger period. Mirae Asset Securities focused on overseas growth led by North America and on improving profitability in the third quarter.

On products, the company said it is preparing B2B solutions and a home healthcare app for ongoing body composition management of patients on GLP-1 treatment. It is also studying AI features that predict changes in body composition.

A company official expressed expectation that US sales would keep growing at a high rate over the long term. Software accounted for only 3.4% of first-half sales, so converting an equipment-centered model into one with recurring revenue remains a task. Securities estimates depend on the assumptions in each report.

The next checkpoints are the fourth-quarter 2026 results and the 2026 annual report. The key questions are whether fourth-quarter sales match the projected growth and whether net income attributable to owners recovers from the third-quarter level of KRW 4.58 billion.

07

Valuation

PER
12.5×
PBR
1.5×
ROE
13.3%
EPS
₩3,101
BPS
₩25,669
Dividend per share
₩600

Valuation can be read through the relationship between the share price and earnings levels. Operating profit has risen for three consecutive quarters, but net income attributable to owners over the last four quarters totals KRW 41.5 billion, and the bottom-line level has been lower since the second quarter of 2026.

The price-to-book ratio sits above 1x, so the stock trades at a premium to book value. Of total equity of KRW 319.8 billion, the portion attributable to owners is KRW 317.8 billion.

Sangsangin Securities said in its October 2026 report that it applied a price-to-earnings multiple of 22x to reflect rising demand for body composition monitoring linked to GLP-1 drugs. Mirae Asset Securities presented a target price of KRW 100,000 in a report covered in November 2026 and kept its buy rating.

Daol Investment & Securities did not present an investment rating or a fair value. On an annual basis, earnings peaked in 2023 and then declined, and in 2026 quarterly operating profit has been recovering.

How the multiple reads will depend on whether the operating profit recovery carries through to net income attributable to owners.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Fast overseas sales growth

North American sales rose 34% to KRW 31.1 billion in the third quarter, and first-half US sales grew 37.3% to about KRW 51 billion. Europe and Mexico also grew faster than 40%. The US and Europe accounted for 66.8% of the first-half sales increase, so overseas markets are driving top-line growth.

Operating profit and margin gains

Third-quarter operating profit rose 96.5% to KRW 19.3 billion, and the operating margin was reported at 27.1%, up from 24.2% in the prior quarter. Analysts attributed the gain to higher sales of premium professional-use products and cost efficiency. High-end models priced at USD 15,000 or more are reported to carry higher profitability than standard products.

Demand for body composition management and low penetration

A company official said demand is growing for managing body composition rather than body weight alone, as GLP-1 obesity drugs spread. The company said penetration of the analysis market remains low, leaving room for growth. Sangsangin Securities estimated that 2026 sales would rise 23.9% year on year.

09

Bear factors

Slowing net income attributable to owners

Net income attributable to owners fell 52.5% year on year to KRW 4.58 billion in the third quarter. It had peaked at KRW 16.3 billion in the first quarter of 2026 and has declined in each of the two quarters since.

This runs against the operating profit trend, so the gains at the operating line have not flowed through to the bottom line. Whether FX volatility and one-off costs weigh on net income again next quarter is the point to check.

Weakness in domestic sales and medical devices

Domestic sales fell 15% to KRW 8.6 billion in the third quarter, and medical device sales fell 5% to KRW 2.9 billion. Total sales declined 2.7% from the prior quarter. Analysts noted that the recovery of the medical device segment needs to be checked. Because overseas growth is offsetting domestic declines, a slowdown abroad would weigh more heavily on results.

Equipment-heavy model and FX exposure

Body composition analyzers made up 70.8% of first-half sales, so dependence on equipment sales is high. Exports were 87.3% of first-half sales, which leaves results exposed to currency moves.

10

Risk factors

FX and export dependence

With exports at 87.3% of first-half 2026 sales, currency moves feed directly into revenue and profit. FX volatility was also cited as a factor in the third-quarter decline in net income. A change in the won's direction would alter both the won value of overseas sales and export growth rates.

Concentration in North America

North America is the largest region, with third-quarter sales of KRW 31.1 billion. A slowdown in its growth could affect total results. Because US sales lean heavily on hospitals and medical institutions, changes in that channel could also have an impact.

Demand structure and one-off items

Demand for body composition management tied to obesity drugs is a growth driver the company emphasizes, but shifts in treatment patterns could change that outlook. One-off costs and FX gains and losses have kept net income moving differently from operating profit. Software accounts for just 3.4% of sales, so the recurring revenue base remains thin.

11

What to watch next

  1. January–February 2027 (release date not yet fixed)

    Preliminary fourth-quarter 2026 results. The checks are whether sales growth matches the securities estimates and whether net income attributable to owners recovers from KRW 4.58 billion in the third quarter.

  2. End of March 2027

    Filing deadline for the 2026 annual report (90 days after year-end). It is the point to confirm how the annual operating margin moved from 15.7% in 2025 and whether preliminary figures changed after audit.

  3. May 15, 2027

    Filing deadline for the first-quarter 2027 report (45 days after quarter-end). It is the point to check whether North American and European sales growth holds and whether the domestic and medical device weakness recovers.

12

Overall view

InBody's third-quarter 2026 results show that overseas sales growth and cost efficiency lifted operating profit. On the disclosed basis, operating profit has risen for three consecutive quarters since the first quarter of 2026, and press reports put the operating margin higher.

Net income attributable to owners, however, fell 52.5% to KRW 4.58 billion in the same quarter, with FX volatility and one-off costs cited as causes.

Over the annual period, sales have risen for three straight years since 2023, but the operating margin narrowed from 25.4% in 2022 to 15.7% in 2025, and net income attributable to owners declined in 2024 and 2025.

Overseas markets led by North America, Europe and Mexico are driving growth, while domestic sales and medical devices are weaker. Securities estimates and target prices depend on the assumptions in each report and were presented at different dates.

The next checkpoints are the preliminary fourth-quarter 2026 results and the 2026 annual report, and the central question is whether the operating profit gains reach net income attributable to owners. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. vegannews.co.kr
  2. kormedi.com
  3. pinpointnews.co.kr
  4. ket.kr
  5. hankyung.com
  6. greened.kr
  7. cbci.co.kr
  8. markets.hankyung.com
  9. view.asiae.co.kr
  10. mt.co.kr
  11. medipana.com
  12. hkn24.com
  13. bloter.net
  14. hankyung.com
  15. dailypharm.com
  16. thescoop.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis